Revvity Reports Q3 2026 Earnings and Raises Full-Year Guidance

Revvity, Inc. (NYSE: RVTY) Q3 2026 Financial Results Overview

Revvity, Inc. filed a Form 8-K under Items 2.02 (Results of Operations and Financial Condition) and 8.01 (Other Events), announcing its financial results for the third quarter ended October 4, 2026, and updating pro forma financials regarding the planned divestiture of its China Immunodiagnostics business.

Key Financial Highlights

• Revenue: Reported revenue rose to $729.0 million, compared to $698.9 million in Q3 2025. Pro forma revenue reached $709.6 million, representing a 7% year-over-year increase and 7% pro forma organic growth.
• Operating Performance:
  • GAAP Operating Income was $95.1 million (13.1% margin), up from $81.9 million (11.7% margin) in Q3 2025.
  • Adjusted Operating Income climbed to $209.0 million (28.7% margin), up from $182.0 million (26.1% margin).
• Earnings Per Share (EPS):
  • GAAP EPS from continuing operations reached $0.56 (vs. $0.41 in Q3 2025).
  • Adjusted EPS from continuing operations came in at $1.38 (vs. $1.18 in Q3 2025).
  • Pro forma adjusted EPS was $1.37 (vs. $1.13 in Q3 2025).

Segment Breakdown

• Life Sciences: Third-quarter revenue reached $380 million, up 11% on a pro forma basis (9% organic). Adjusted operating profit margin expanded to 31.5% from 29.5%.
• Diagnostics: Third-quarter revenue was $349 million, delivering 4% pro forma revenue growth (5% organic). Adjusted operating profit margin improved significantly to 29.9% from 25.1%.

FY 2026 Guidance & Strategic Updates

• Full-Year Outlook Raised: On a pro forma basis, Revvity forecasts total revenue of approximately $2.86 billion, pro forma organic growth of ~5%, and pro forma adjusted EPS between $5.40 and $5.45.
• China IDX Divestiture: The Company reiterated terms for the definitive agreement signed July 31, 2026, to divest substantially all assets of its Immunodiagnostics business in China for up to $200 million, expected to close by year-end 2027.